Literature DB >> 63654

Hyperinsulinism of hepatic cirrhosis: Diminished degradation or hypersecretion?

D G Johnson, K G Alberti, O K Faber, C Binder.   

Abstract

The breakdown of proinsulin in the pancreatic beta cell yields insulin and C-peptide which are secreted in equimolar amounts. Unlike insulin, C-peptide is not degraded significantly by the liver, so that its measurement should give a better assessment of insulin secretion than estimation of peripheral insulin levels alone; particularly in the presence of hepatic dysfunction. Plasma C-peptide and insulin response to an oral glucose load have therefore been assessed in 14 cirrhotic and 7 normal subjects. Cirrhotic patients were divided into hyperinsulinaemic and normoinsulinaemic groups based on fasting plasma-insulin concentrations. Fasting blood-blucose and plasma-C-peptide concentrations were the same in normal and cirrhotic subjects, suggesting that basal pancreatic insulin secretion was the same in all subjects. Thus the C-peptide/insulin ratio was significantly decreased in hyperinsulinaemic subjects (2-13 +/- 0-31, compared with 4-63 +/- 0-48 in controls). After oral glucose, the two groups of cirrhotic patients showed the same glucose intolerance. C-peptide concentrations were also the same but insulin concentrations were markedly increased in the hyperinsulinaemic group. It is suggested that pancreatic insulin secretion is not increased in cirrhosis and that the peripheral hyperinsulinism is due solely to decreased hepatic insulin degradation secondary to either spontaneous portal-systemic shunting or to parenchymal damage.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 63654     DOI: 10.1016/s0140-6736(77)91652-x

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  37 in total

1.  A study on the hyperinsulinism of late pregnancy.

Authors:  I Piva; G Erle; M Thiella; L Lora; M Strazzabosco; N Sicolo; G Federspil
Journal:  J Endocrinol Invest       Date:  1991-11       Impact factor: 4.256

Review 2.  Interaction between hepatitis C virus and metabolic factors.

Authors:  Yasunori Kawaguchi; Toshihiko Mizuta
Journal:  World J Gastroenterol       Date:  2014-03-21       Impact factor: 5.742

3.  The risk of transient postprandial oxyhypoglycemia in nonalcoholic fatty liver disease.

Authors:  Reona Morio; Hideyuki Hyogo; Masahiro Hatooka; Kei Morio; Hiromi Kan; Tomoki Kobayashi; Tomokazu Kawaoka; Masataka Tsuge; Akira Hiramatsu; Michio Imamura; Yoshiiku Kawakami; Hiroshi Aikata; Hidenori Ochi; Yoneda Masayasu; Kazuaki Chayama
Journal:  J Gastroenterol       Date:  2016-06-28       Impact factor: 7.527

4.  Insulin resistance and chronic liver disease.

Authors:  Takumi Kawaguchi; Eitaro Taniguchi; Minoru Itou; Masahiro Sakata; Shuji Sumie; Michio Sata
Journal:  World J Hepatol       Date:  2011-05-27

Review 5.  Some clinical features of liver cell failure: an appraisal of their causes.

Authors:  A E Read
Journal:  Gut       Date:  1978-06       Impact factor: 23.059

6.  Insulin and glucagon concentrations in portal and peripheral veins in patients with hepatic cirrhosis.

Authors:  A V Greco; F Crucitti; G Ghirlanda; R Manna; L Altomonte; A G Rebuzzi; A Bertoli
Journal:  Diabetologia       Date:  1979-07       Impact factor: 10.122

7.  Insulin, C-peptide and glucagon levels during OGTT in hepatic cirrhosis and in patients with prehepatic block.

Authors:  L Gerö; L Korányi; F Szalay; B Büki; G Tamás
Journal:  Acta Diabetol Lat       Date:  1982 Jan-Mar

8.  Kinetics of human connecting peptide in normal and diabetic subjects.

Authors:  O K Faber; C Hagen; C Binder; J Markussen; V K Naithani; P M Blix; H Kuzuya; D L Horwitz; A H Rubenstein; N Rossing
Journal:  J Clin Invest       Date:  1978-07       Impact factor: 14.808

9.  Correction of altered plasma amino acid pattern in cirrhosis of the liver by somatostatin.

Authors:  B Limberg; B Kommerell
Journal:  Gut       Date:  1984-11       Impact factor: 23.059

Review 10.  The Measurement of Insulin Clearance.

Authors:  Francesca Piccinini; Richard N Bergman
Journal:  Diabetes Care       Date:  2020-09       Impact factor: 19.112

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.